Stock and Hong Kong stock innovative medicine sector trend this week
In the fourth week of April 2022, a total of 22 stocks in the innovative drug sector in mainland and Hong Kong rose, 35 stocks fell, and the trading of cornerstone pharmaceutical-b, Lepu biological-b and Deqi pharmaceutical-b was suspended. Among them, the top three gainers are Corning Jerry pharmaceutical-b (+ 18.97%), Nanmo Biology (+ 15.47%), Maibo pharmaceutical-b (+ 14.86%). The top three declines were heyu-b (- 16.23%), Yunding xinyao-b (- 15.6%) and Jiangsu Aidea Pharmaceutical Co.Ltd(688488) (- 13.61%). This week, the A-share innovative drug sector fell 8.83%, underperforming the CSI 300 index by 8.9pp, and biomedicine fell 0.03%. In the past six months, A-share innovative drugs have fallen by 23.41%, underperforming the CSI 300 index by 7.65pp, and biomedicine has fallen by 26.22%. This week, the innovative drug sector of Hong Kong stocks rose 2.85%, outperforming the Hang Seng Index by 0.67pp, and Hang Seng healthcare rose 2.22%. In the past six months, innovative drugs in Hong Kong stocks fell by 25.48%, underperforming the Hang Seng Index by 9.94pp, and Hang Seng healthcare fell by 33.59%.
Progress of key innovative drugs in China
In April, a total of seven new drugs were approved for marketing in China. This week, a new indication was approved for a drug in China, and Baiji Shenzhou’s belintoumab was approved for the treatment of recurrent or refractory precursor B-cell acute lymphoblastic leukemia in adults and children.
Progress of overseas key innovative drugs
In April, 9 new drugs were approved by FDA and 3 new drugs were approved this week, vivjoa, camzyos and cuvrior. In April, no new drugs were approved for marketing in Europe. In April, no new drugs were approved for marketing in Japan.
This week’s special topic – 2022asco domestic new drug selection
In 2022, ASCO was selected into 112 clinical trials of Chinese pharmaceutical enterprises, including 73 monoclonal antibodies, 16 double antibodies, car-t8 and adc3. The top five enterprises with the largest number of clinical trials are Baiji Shenzhou, Jiangsu Hengrui Medicine Co.Ltd(600276) , Yasheng pharmaceutical, Shiyao group and Xinda biology, and the number of drugs selected are 11, 8, 7, 7 and 7 respectively. The top 5 targets involved in clinical trials are PD-1 / L1, HER2, VEGFR, EGFR and Btk, with the number of 28, 12, 9, 8 and 5 respectively.
Progress of global key innovative drug transactions this week
This week, there were two key transactions in the world, and one key transaction disclosed the amount. Zhongzhengda Tianqing and Anyuan pharmaceutical have reached strategic cooperation on the development and commercialization of the rights and interests of ap025 and ap026 in China. By signing the license agreement, Anyuan pharmaceutical will receive a down payment and milestone payment of up to RMB 342 million, as well as a single digit graded net sales royalty.
Risk warning: drug price reduction risk; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure.
